NCT04416568 2025-12-17
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04551430 2025-11-12
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05836571 2025-10-20
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04480502 2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT04118166 2023-12-12
Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
Stanford University
Phase 2 Completed
NCT02500797 2023-10-17
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00140855 2022-10-12
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
Ludwig Institute for Cancer Research
Phase 2 Terminated
NCT02982486 2017-11-01
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Assaf-Harofeh Medical Center
Phase 2 Unknown